Rivera-Rivera Leonardo A, Eisenmenger Laura, Cody Karly A, Reher Thomas, Betthauser Tobey, Cadman Robert V, Rowley Howard A, Carlsson Cynthia M, Chin Nathaniel A, Johnson Sterling C, Johnson Kevin M
Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Alzheimers Dement (Amst). 2021 Dec 31;13(1):e12253. doi: 10.1002/dad2.12253. eCollection 2021.
This work investigated the relationship between cerebrovascular disease (CVD) markers and Alzheimer's disease (AD) biomarkers of amyloid beta deposition, and neurofibrillary tau tangles in subjects spanning the AD clinical spectrum.
A total of 136 subjects participated in this study. Four groups were established based on AD biomarker positivity from positron emission tomography (amyloid [A] and tau [T]) and clinical diagnosis (cognitively normal [CN] and impaired [IM]). CVD markers were derived from structural and quantitative magnetic resonance imaging data.
Transcapillary pulse wave delay was significantly longer in controls compared to AT biomarker-confirmed groups (A+/T-/CN < .001, A+/T+/CN < .001, A+/T+/IM = .003). Intracranial low-frequency oscillations were diminished in AT biomarker-confirmed groups both CN and impaired (A+/T-/CN = .039, A+/T+/CN = .007, A+/T+/IM = .011). A significantly higher presence of microhemorrhages was measured in A+/T+/CN compared to controls ( = .006).
Cerebrovascular markers indicate increased vessel stiffness and reduced vasomotion in AT biomarker-positive subjects during preclinical AD.
本研究调查了在整个阿尔茨海默病（AD）临床谱系的受试者中，脑血管疾病（CVD）标志物与淀粉样β沉积、神经原纤维缠结的AD生物标志物之间的关系。
共有136名受试者参与了本研究。根据正电子发射断层扫描（淀粉样蛋白[A]和tau蛋白[T]）的AD生物标志物阳性情况以及临床诊断（认知正常[CN]和受损[IM]）建立了四组。CVD标志物来自结构和定量磁共振成像数据。
与AT生物标志物确诊组相比，对照组的跨毛细血管脉搏波延迟明显更长（A + /T - /CN <.001，A + /T + /CN <.001，A + /T + /IM =.003）。在AT生物标志物确诊的CN组和受损组中，颅内低频振荡均减弱（A + /T - /CN =.039，A + /T + /CN =.007，A + /T + /IM =.011）。与对照组相比，A + /T + /CN组的微出血发生率显著更高（ =.006）。
脑血管标志物表明，在临床前AD期间，AT生物标志物阳性的受试者血管僵硬度增加，血管运动减少。
